trending Market Intelligence /marketintelligence/en/news-insights/trending/zaZWXem1vqsQv3J6xiultA2 content esgSubNav
In This List

Tilray, Novartis unit to jointly distribute medical cannabis worldwide

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Tilray, Novartis unit to jointly distribute medical cannabis worldwide

Tilray Inc., a Canadian cannabis company, has entered an agreement with Novartis AG's Swiss generics and biosimilars unit Sandoz AG to increase the availability of medical cannabis worldwide, as of Dec. 18.

The global collaboration agreement, which will focus on the commercialization and distribution of Tilray's non-smokable and non-combustible medical cannabis products, expands on a previous partnership between Tilray and Sandoz Canada Inc. to co-market products in Canada.

Under the new partnership, Tilray and Sandoz AG will jointly distribute medical cannabis in regions where the substance is approved for medical use. The companies may co-brand products and jointly develop new products as well.

Nanaimo, British Columbia-based Tilray, which now trades on the Nasdaq Global Select Market, currently has products available in 12 countries. In addition to producing medical marijuana, Tilray plans to provide cannabis products for Canada's adult recreational use market.